Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

Kennedy Jr., who has been tapped by Trump to lead the HHS, has been critical of Ozempic and other weight loss drugs.

The Ipsos survey of 1,078 adults found 24% of people would use weight-loss jabs if they were provided for free by the health ...

Credit: Jo Panuwat D/Shutterstock. On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Wegovy is the world’s first weekly glucagon-like peptide-1 receptor agonist for long-term weight management. China’s National ...

MBX Biosciences (MBX) completed the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the company’s long-acting glucagon-like peptide 1 receptor antagonist ...

About MBX 1416 MBX 1416 is an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist in development as a potential treatment for PBH. It was designed using the Company’s novel ...

Modern medical innovations continue to transform treatment approaches for chronic conditions, and Ozempic stands at the ...